Metcela

Share on: 
Website: Metcela
Business Area(s): 
Description: 

Metcela’s core patented technology involves a particular population of cardiac fibroblasts, namely VCAM-1-positive cardiac fibroblast (VCF)*. VCAM-1-positive cardiac fibroblasts are known to replenish and re-establish the damaged cardiac muscles and the microenvironment surrounding them.

Location(s): 
Yamagata
Japan